دورية أكاديمية
Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2.
| العنوان: | Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2. |
|---|---|
| المؤلفون: | Chau NVV, Nguyet LA, Dung NT, Quang VM, Truong NT, Toan LM, Hung LM, Man DNH, Khoa DB, Phong NT, Ngoc NM, Thao HP, Ty DTB, Thanh PB, Ny NTH, Thanh LK, Thuy CT, Anh NT, Hong NTT, Nhu LNT, Yen LM, Thwaites G, Thanh TT, Tan LV |
| مؤلفون مشاركون: | for OUCRU COVID-19 Research Group |
| المصدر: | The American journal of tropical medicine and hygiene [Am J Trop Med Hyg] 2022 Nov 30; Vol. 108 (1), pp. 137-144. Date of Electronic Publication: 2022 Nov 30 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Tropical Medicine and Hygiene Country of Publication: United States NLM ID: 0370507 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1476-1645 (Electronic) Linking ISSN: 00029637 NLM ISO Abbreviation: Am J Trop Med Hyg Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Northbrook, IL : American Society of Tropical Medicine and Hygiene Original Publication: Baltimore. |
| مواضيع طبية MeSH: | BNT162 Vaccine* , COVID-19*/prevention & control, Humans ; Antibodies, Neutralizing ; Kinetics ; Immunization, Secondary ; Southeast Asian People ; SARS-CoV-2/genetics ; Vaccination ; ChAdOx1 nCoV-19 ; Breakthrough Infections ; Health Personnel ; Antibodies, Viral |
| مستخلص: | We studied the development and persistence of neutralizing antibodies against SARS-CoV-2 ancestral strain, and Delta and Omicron (BA.1 and BA.2) variants in Vietnamese healthcare workers (HCWs) up to 15 weeks after booster vaccination. We included 47 HCWs, including group 1 (G1, N = 21) and group 2 (G2; N = 26) without and with breakthrough Delta variant infection before booster immunization, respectively). The study participants had completed primary immunization with ChAdOx1-S and booster vaccination with BNT162b2. Neutralizing antibodies were measured using a surrogate virus neutralization assay. Of the 21 study participants in G1, neutralizing antibodies against ancestral strain, Delta variant, BA.1, and BA.2 were (almost) abolished at month 8 after the second dose, but all had detectable neutralizing antibodies to the study viruses at week 2 post booster dose. Of the 26 study participants in G2, neutralizing antibody levels to BA.1 and BA.2 were significantly higher than those to the corresponding viruses measured at week 2 post breakthrough infection and before the booster dose. At week 15 post booster vaccination, neutralizing antibodies to BA.1 and BA.2 dropped significantly, with more profound changes observed in those without breakthrough Delta variant infection. Booster vaccination enhanced neutralizing activities against ancestral strain and Delta variant compared with those induced by primary vaccination. These responses were maintained at high levels for at least 15 weeks. Our findings emphasize the importance of the first booster dose in producing cross-neutralizing antibodies against Omicron variant. A second booster to maintain long-term vaccine effectiveness against the currently circulating variants merits further research. |
| References: | Nat Microbiol. 2022 Dec;7(12):1996-2010. (PMID: 36357712) N Engl J Med. 2022 Mar 31;386(13):1288-1290. (PMID: 35139269) Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387) J Infect Dis. 2022 Oct 17;226(8):1385-1390. (PMID: 35482442) Cell. 2022 Feb 3;185(3):467-484.e15. (PMID: 35081335) Am J Trop Med Hyg. 2022 Jan 07;106(2):556-561. (PMID: 34996048) Lancet Microbe. 2022 Jun;3(6):e404. (PMID: 35373159) EClinicalMedicine. 2021 Nov;41:101143. (PMID: 34608454) Nat Med. 2022 Mar;28(3):486-489. (PMID: 35051989) N Engl J Med. 2022 Apr 28;386(17):1603-1614. (PMID: 35417631) Nat Med. 2022 Mar;28(3):472-476. (PMID: 35042228) JAMA Netw Open. 2022 May 2;5(5):e2212073. (PMID: 35560054) N Engl J Med. 2021 Dec 9;385(24):e85. (PMID: 34706170) MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. (PMID: 35176007) Lancet Infect Dis. 2022 Jun;22(6):766-767. (PMID: 35427493) Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169) Nat Microbiol. 2022 Aug;7(8):1161-1179. (PMID: 35798890) Cell. 2022 Mar 3;185(5):847-859.e11. (PMID: 35139340) Science. 2022 Jan 07;375(6576):43-50. (PMID: 34812653) N Engl J Med. 2022 Apr 21;386(16):1579-1580. (PMID: 35294809) J Infect. 2021 Jun;82(6):276-316. (PMID: 33774018) Cell Mol Immunol. 2022 Feb;19(2):293-295. (PMID: 35017716) Lancet. 2022 Apr 2;399(10332):1303-1312. (PMID: 35305296) |
| معلومات مُعتمدة: | 204904/Z/16/Z United Kingdom WT_ Wellcome Trust |
| المشرفين على المادة: | 0 (BNT162 Vaccine) 0 (Antibodies, Neutralizing) B5S3K2V0G8 (ChAdOx1 nCoV-19) 0 (Antibodies, Viral) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20221130 Date Completed: 20230113 Latest Revision: 20240214 |
| رمز التحديث: | 20240214 |
| مُعرف محوري في PubMed: | PMC9833090 |
| DOI: | 10.4269/ajtmh.22-0434 |
| PMID: | 36450229 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1476-1645 |
|---|---|
| DOI: | 10.4269/ajtmh.22-0434 |